About the Company
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry (for example, contract research organization services) and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing. According to the company, it supported the development of approximately 85% of novel FDA-approved drugs in 2021.Its customers include leading pharmaceutical, biotechnology, agrochemical, government, and academic organization around the globe. The company has over 90 facilities, operates in 20 countries, and employs approximately 18,400 people worldwide. Charles River Laboratories is often criticized by animal rights activists who condemn the company's usage of dogs and non-human primates for pharmaceutical purposes. The company is also a major harvester of horseshoe crab blood.
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological Research
Employees
12903
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CRL News
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.
Charles River Laboratories International Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories’ Directors ...
Johnson Fistel, LLP ( a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River ...
Charles River Laboratories International Inc. (CRL) Stock Price and Analyst Predictions
Charles River Laboratories International Inc. (NYSE: CRL) has a price-to-earnings ratio that is above its average at 24.71x. The stock has a 36-month beta value of 1.44. Opinions on the stock are ...
Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Is Going Strong: Is the Market Following Fundamentals?
Charles River Laboratories International (NYSE:CRL) has had a great run on the share market with its stock up by a significant 16% over the last three months. Given the company's impressive ...
Innovating drug development: Charles River embracing alternatives to animal testing
Charles River Laboratories International, Inc. has unveiled its Alternative Methods Advancement Project (AMAP), a strong ...
CRL Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...
Charles River Laboratories International (NYSE: CRL)
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices ...
Charles River Laboratories International Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Charles River Laboratories International Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Loading the latest forecasts...